Summary
Becton Dickinson & Co. (BDX) reported its first quarter fiscal year 2016 results on February 4, 2016, for the period ending December 31, 2015. The company experienced a significant revenue increase of 45.6% year-over-year, reaching $2.986 billion. This growth was primarily driven by the inclusion of CareFusion's results, acquired in March 2015, which contributed $1.016 billion in revenue and $137 million in operating income to the Medical segment. Excluding the impact of foreign currency fluctuations, revenue grew by a robust 53.5% on a constant currency basis. Despite the substantial revenue growth, net income decreased to $229 million from $236 million in the prior year, leading to a dip in diluted earnings per share to $1.06 from $1.20. This decline was impacted by higher operating costs, including acquisition-related expenses ($121 million), increased R&D spending, and a significant increase in intangible asset amortization related to the CareFusion acquisition. The company generated $463 million in cash from operating activities, demonstrating solid cash flow generation. BDX also continued to return value to shareholders through dividends, paying out $140 million in the quarter. Investors should closely monitor the integration of CareFusion and the ongoing impact of acquisition-related costs and amortization on profitability.
Financial Highlights
52 data points| Revenue | $2.99B |
| Cost of Revenue | $1.58B |
| Gross Profit | $1.41B |
| R&D Expenses | $187.00M |
| SG&A Expenses | $748.00M |
| Operating Expenses | $2.63B |
| Operating Income | $352.00M |
| Interest Expense | $97.00M |
| Net Income | $229.00M |
| EPS (Basic) | $1.08 |
| EPS (Diluted) | $1.06 |
| Shares Outstanding (Basic) | 211.69M |
| Shares Outstanding (Diluted) | 216.29M |
Key Highlights
- 1Total revenues surged by 45.6% to $2.986 billion, largely due to the acquisition of CareFusion, which added $1.016 billion in revenue to the Medical segment.
- 2Diluted earnings per share decreased to $1.06 from $1.20 in the prior year, impacted by higher acquisition-related costs and amortization expenses.
- 3Operating income increased to $352 million from $349 million, despite increased costs associated with the CareFusion acquisition.
- 4Cash flow from operations remained strong, increasing to $463 million from $286 million in the prior year's comparable period.
- 5The company paid $140 million in dividends to shareholders, signaling a continued commitment to returning value.
- 6Significant increase in intangible asset amortization ($152 million vs $20 million) primarily due to the CareFusion acquisition.
- 7The Medical segment saw substantial growth, with revenues increasing by 91.6% to $2.054 billion, driven by CareFusion and legacy product sales.